FDA-Approved Peptides

Type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).

Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Type 2 diabetes (Victoza) and chronic weight management (Saxenda).

Type 2 diabetes; also indicated to reduce cardiovascular risk in certain patients.

Type 2 diabetes.

Reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients.

Chronic weight management in specific rare genetic forms of obesity (POMC, PCSK1, LEPR deficiency).

Acromegaly, carcinoid syndrome and VIPomas (neuroendocrine tumors).

Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Osteoporosis at high risk of fracture.

Hypoactive sexual desire disorder (HSDD) in premenopausal women.